Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48103, USA.
Hepatology. 2010 Aug;52(2):730-42. doi: 10.1002/hep.23696.
Idiosyncratic drug-induced liver injury (DILI) is an important but relatively infrequent cause of potentially severe acute and chronic liver injury. The aim of this clinical research workshop was to review and attempt to standardize the current nomenclature and terminology used in DILI research. Because DILI is a diagnosis of exclusion, selected elements of the medical history, laboratory tests, and previous reports were proposed to improve causality assessment. Definitions and diagnostic criteria regarding the onset of DILI, evolution of liver injury, risk factors, and mandatory testing versus optional testing for competing causes were reviewed. In addition, the role of intentional and inadvertent rechallenge, liver histology, and host genetic polymorphisms in establishing the diagnosis and prognosis of DILI were reviewed. Consensus was established regarding the need to develop a web-of-knowledge database that provides concise, reliable, and updated information on cases of liver injury due to drugs and herbal and dietary supplements. In addition, the need to develop drug-specific computerized causality assessment methods that are derived from prospectively phenotyped cases was a high priority. Proposed scales for grading DILI severity and assessing the likelihood of an agent causing DILI and written criteria for improving the reliability, accuracy, and reproducibility of expert opinion were reviewed. Finally, the unique challenges of assessing causality in children, patients with underlying liver disease, and subjects taking herbal and dietary supplements were discussed.
Workshop participants concluded that multicenter referral networks enrolling patients with suspected DILI according to standardized methodologies are needed. These networks should also collect biological samples that may provide crucial insights into the mechanism(s) of DILI with the ultimate aim of preventing future cases of DILI.
药物诱导的肝损伤(DILI)是一种重要但相对罕见的潜在严重急性和慢性肝损伤的原因。本次临床研究研讨会的目的是回顾并尝试规范 DILI 研究中当前使用的命名法和术语。由于 DILI 是一种排除性诊断,因此提出了病史、实验室检查和以前报告中的某些元素,以改善因果关系评估。对 DILI 的发病、肝损伤的演变、危险因素以及针对竞争原因的强制性和可选检测进行了定义和诊断标准的审查。此外,还审查了有意和无意再挑战、肝组织学以及宿主遗传多态性在确立 DILI 的诊断和预后中的作用。一致认为需要开发一个知识网络数据库,该数据库提供有关药物、草药和膳食补充剂引起的肝损伤病例的简明、可靠和最新信息。此外,开发源自前瞻性表型病例的特定药物计算机因果关系评估方法是当务之急。还审查了用于分级 DILI 严重程度和评估药物引起 DILI 的可能性的评分量表,以及用于提高专家意见的可靠性、准确性和可重复性的书面标准。最后,讨论了在评估儿童、潜在肝病患者和服用草药和膳食补充剂的受试者的因果关系方面的独特挑战。
与会者认为,需要根据标准化方法招募疑似 DILI 患者的多中心转诊网络。这些网络还应收集生物样本,这可能为 DILI 的机制提供重要见解,最终目的是预防未来的 DILI 病例。